Navigation Links
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
Date:8/4/2014

SARASOTA, Fla., Aug. 4, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.

Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will present preclinical and clinical data for anatabine citrate, a small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr Mullan will outline the company's regulatory strategy and ongoing drug development initiatives advancing the lead molecule into phase I and phase II studies.

About BioPharm America 2014

BioPharm America™ is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe® and BIO-Europe Spring®.

Additional links and information:

Follow BioPharm America 2014 on Twitter:  @EBDGroup (hashtag: #BPA14).

About Anatabine Citrate:

Rock Creek Pharmaceuticals' Anatabine Citrate is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical in vitro and in vivo studies resulting in peer reviewed and published scientific journal articles, covering inflammatory models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. In addition, the company's compilation of human exposure, safety and tolerability data, provides important insights for future clinical pathway progression.

About Rock Creek Pharmaceuticals, Inc.:

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for inflammatory conditions and behavioral health.  Additionally, through its subsidiary RCP Development, the Company is engaged in the manufacturing and sale of nutraceutical dietary supplements designed to promote maintenance of a healthy metabolism and lifestyle. 

For more information, visit: http://www.rockcreekpharma.com

CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharma.com
203-216-2028

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q Report filed on May 12, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

Logo - http://photos.prnewswire.com/prnh/20140804/133073


'/>"/>
SOURCE Rock Creek Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
2. Creekridge Capital Signs Several New Vendor Partners
3. Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
4. Creekridge Breaks Monthly and Quarterly Volume Records
5. Creekridge Capital Grows Healthcare Sales Team
6. Creekridge Capital Launches Vendor Sales Training Program
7. Creekridge Capital Expands Healthcare Sales Team
8. Creekridge Capital Adds Revolving Credit Specialist
9. Creekridge Capital Announces Record Volume
10. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
11. Creekridge Capital Continues Vendor Growth within Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced it has earned a spot ... 2017" list. The Company was ranked among 500 U.S. ... Employers and Healthcare Equipment and Services. The ... on an anonymous, independent survey of over 30,000 employees ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information ... announced the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • ... the healthcare industry today. , Out of more than 500 submissions, 100 winners ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, ... this month as a Guest Speaker and Contributor to a weeklong series of classes, ... Purpose. , Walter Schindler and SAIL Capital have received ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... chat as a standard feature on its secure clinical communication platform. The platform ... to video depending on the type and urgency of a situation. , ...
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart guided journaling ... infographic on the current state of anxiety in support of National Mental Health Awareness ... in April 2017 and benchmarked general anxiety levels as well as identified the top ...
(Date:5/22/2017)... ... May 22, 2017 , ... Today, Our Urgent Care ... with a public ribbon cutting ceremony. Since opening over a month ago, ... to the emergency room. The new Our Urgent Care walk-in clinic is located ...
Breaking Medicine News(10 mins):